Bio-Techne Corp at Nasdaq London Investor Conference Transcript
All right. I guess the music is off, and that is our queue. So thank you all for joining us today for our conversation. We'll kick things off, and then you'll do most of talking to tell this incredible story for us. But for everybody, I'm Jack Cassel, Senior Vice President with Nasdaq. And I'm excited for our discussion today with the Chief Executive Officer, Kim Kelderman; and Chief Financial Officer, Jim Hippel, for Bio-Techne.
So maybe for the audience, let's level set with just an overview on the business.
Thank you, Jack, first of all, for having us and hosting the conference. We're very excited, and we are 15 years in the making. So Bio-Techne itself, 50 years old. However, we say old, the core business that we have created over these 50 years is 7,000 proteins and 400,000 antibodies, basically lego blocks for any life science tools, laboratory that wants to make progress. So we're deeply entrenched in everything research, really.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
